Allergan Strikes Back at ValeantMark Melin
Let the argument between the bean counters at Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and research and development scientists at Allergan, Inc. (NYSE:AGN) begin!
Questioning research and development cuts
After Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) launched a $46 billion cash and stock bid to roll-up Allergan, Inc. (NYSE . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible